Piper Sandler reiterates Kestra Medical stock rating on sales momentum By Investing.com

Piper Sandler reiterated an Overweight rating and $30 price target on Kestra Medical Technologies, implying 45% upside from the $20.63 share price. The firm cited accelerating wearable cardioverter defibrillator market growth, improving algorithm and registry data, and management commentary that revenue should see upside into fiscal Q4 ending in April. Despite a Q3 2026 EPS miss of -$0.61 versus -$0.42 expected, revenue still grew nearly 7% above estimates and analysts at Piper Sandler and BTIG remain constructive.

Analysis

KMTS is behaving like a classic early-commercialization hardware winner: the market is starting to underwrite operating leverage before the income statement shows it cleanly. The key second-order effect is that a faster ramp in the sales force and improving wear-time economics should do more than lift top line — it should expand installed-base data density, which in medtech often feeds a self-reinforcing loop into registry strength, clinician comfort, and referral velocity.

The competitive setup matters more than the headline analyst ratings suggest. If KMTS is gaining share in a growing wearable defibrillator market, the more exposed names are likely smaller adjacent monitoring/device platforms that rely on physician mindshare and field sales efficiency rather than pure product differentiation. A sustained lead in algorithm performance plus better real-world data can pressure rivals on both pricing and distribution, especially if hospital systems standardize around one vendor’s workflow.

The main risk is that this is still a narrative stock with execution embedded far ahead of GAAP profitability. Revenue upside over the next 1-2 quarters can keep momentum intact, but any slowdown in wear-time improvement, sales productivity, or conversion from pipeline to placements would quickly compress the multiple because the valuation is already assuming several years of high growth. The most important reversal trigger is not an earnings miss; it is evidence that the sales-force ramp is expensive and not translating into durable unit economics.

Consensus may be underestimating how much of the upside is actually a data-quality and guideline-adoption story, not just a sales growth story. If upcoming clinical or registry signals continue to improve, the stock can rerate before full-year numbers catch up; if not, the premium multiple becomes vulnerable even if growth remains above average. That makes the next two reporting cycles the key window: upside can persist for months, but the burden of proof shifts quickly if estimates keep moving up faster than gross margin or CAC efficiency.

Key Decisions for Investors

• Go long KMTS on pullbacks over the next 1-3 weeks, using the post-analyst-reaffirmation support zone as entry; target a 15-25% move over 3-6 months, with the thesis hinging on continued revenue and wear-time acceleration.
• If options are liquid, buy 3-6 month call spreads on KMTS rather than outright calls to express upside from estimate revisions while limiting valuation-compression risk; structure for roughly 2:1 to 3:1 reward/risk.
• Pair trade: long KMTS / short a basket of smaller-cap medtech names with weaker proprietary data or slower sales-force productivity over 2-4 months; this isolates the premium-vs-growth-quality differential.
• Set a hard risk trigger to reduce exposure if the next quarterly update shows revenue beat without margin or sales-efficiency improvement; that would suggest the ramp is more expensive than the market is pricing.
• For longer-duration portfolios, keep KMTS as a tactical growth exposure only if guideline or registry catalysts are forthcoming; absent that, the multiple becomes vulnerable once the market stops paying for forward estimate momentum.